BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2503383)

  • 21. Accurate assay of dopa decarboxylase by preventing nonenzymatic decarboxylation of dopa.
    Okuno S; Fujisawa H
    Anal Biochem; 1983 Mar; 129(2):412-5. PubMed ID: 6405659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes.
    Verbeek MM; Geurtz PB; Willemsen MA; Wevers RA
    Mol Genet Metab; 2007 Apr; 90(4):363-9. PubMed ID: 17240182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of handling or immobilization on plasma levels of 3,4-dihydroxyphenylalanine, catecholamines, and metabolites in rats.
    Kvetnanský R; Goldstein DS; Weise VK; Holmes C; Szemeredi K; Bagdy G; Kopin IJ
    J Neurochem; 1992 Jun; 58(6):2296-302. PubMed ID: 1573408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis of aromatic L-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots.
    Chen PW; Lee NC; Chien YH; Wu JY; Wang PC; Hwu WL
    Clin Chim Acta; 2014 Apr; 431():19-22. PubMed ID: 24513538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3,4-dihydroxyphenylalanine (dopa) metabolism and retinoic acid induced differentiation in human neuroblastoma.
    Ikeda H; Pastuszko A; Ikegaki N; Kennett RH; Wilson DF
    Neurochem Res; 1994 Dec; 19(12):1487-94. PubMed ID: 7877718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
    Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
    Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of aromatic L-amino acid decarboxylase in serum of various animals by high-performance liquid chromatography with electrochemical detection.
    Rahman MK; Nagatsu T; Kato T
    Life Sci; 1981 Feb; 28(5):485-92. PubMed ID: 6970873
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of pyridoxine deficiency on aromatic L-amino acid decarboxylase in adult rat brain.
    Siow YL; Dakshinamurti K
    Exp Brain Res; 1985; 59(3):575-81. PubMed ID: 3875501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion.
    de Lonlay P; Simon-Carre A; Ribeiro MJ; Boddaert N; Giurgea I; Laborde K; Bellanné-Chantelot C; Verkarre V; Polak M; Rahier J; Syrota A; Seidenwurm D; Nihoul-Fékété C; Robert JJ; Brunelle F; Jaubert F
    J Clin Endocrinol Metab; 2006 Mar; 91(3):933-40. PubMed ID: 16403819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
    Boomsma F; van den Meiracker A; Man in 't Veld A; Schalekamp M
    Life Sci; 1995; 57(19):1753-9. PubMed ID: 7475917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reactions of DOPA (3,4-dihydroxyphenylalanine) decarboxylase with DOPA.
    Minelli A; Charteris AT; Voltattorni CB; John RA
    Biochem J; 1979 Nov; 183(2):361-8. PubMed ID: 534502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
    Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells.
    Rodríguez-Martín E; Canals S; Casarejos MJ; de Bernardo S; Handler A; Mena MA
    J Neurochem; 2001 Aug; 78(3):535-45. PubMed ID: 11483656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma-associated mRNAs in high-risk neuroblastoma patients.
    Uemura S; Lin KS; Mon Thwin KK; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
    Mol Clin Oncol; 2021 Jul; 15(1):137. PubMed ID: 34055352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Production of Dopamine by Aromatic l-Amino Acid Decarboxylase Cells after Spinal Cord Injury.
    Ren LQ; Wienecke J; Hultborn H; Zhang M
    J Neurotrauma; 2016 Jun; 33(12):1150-60. PubMed ID: 26830512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mouse neuroblastoma clone N1E-115: a suitable model for studying the action of dopamine agonists of tyrosine hydroxylase activity.
    Bräutigam M; Dreesen R; Flosbach CW; Herken H
    Biochem Pharmacol; 1982 Apr; 31(7):1279-82. PubMed ID: 6124255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyridoxal 5'-phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B(6) deficiency states.
    Allen GF; Neergheen V; Oppenheim M; Fitzgerald JC; Footitt E; Hyland K; Clayton PT; Land JM; Heales SJ
    J Neurochem; 2010 Jul; 114(1):87-96. PubMed ID: 20403077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increase in plasma 3,4-dihydroxyphenylalanine (DOPA) appearance rate after inhibition of DOPA decarboxylase in humans.
    Eldrup E; Hetland ML; Christensen NJ
    Eur J Clin Invest; 1994 Mar; 24(3):205-11. PubMed ID: 8033956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal 3,4-dihydroxyphenylalanine (dopa) concentrations in plasma and urine of patients with cystic fibrosis.
    Schöni MH; Türler K; Käser H; Kraemer R
    Eur J Clin Invest; 1990 Jun; 20(3):272-8. PubMed ID: 2114988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.